stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Operating cash flow
Ligand Pharmaceuticals Incorporated's operating cash flow for fiscal 2025 was $49.4M, down 49.1% from $97.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $91.0M. Over the past ten years it has ranged from −$29.3M (fiscal 2019) to $194.1M (fiscal 2018); the current reading is higher than 27% of that period. Ligand Pharmaceuticals Incorporated ranks 30th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $49.4M | (49.14%) |
| FY2024 | $97.0M | 95.75% |
| FY2023 | $49.6M | (64.04%) |
| FY2022 | $137.9M | 74.94% |
| FY2021 | $78.8M | 44.36% |
| FY2020 | $54.6M | — |
| FY2019 | −$29.3M | — |
| FY2018 | $194.1M | 119.10% |
| FY2017 | $88.6M | 45.84% |
| FY2016 | $60.7M | 45.55% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$27.6M | — |
| Jun 2026 | $24.0M | (50.67%) |
| Mar 2026 | $48.7M | 6.05% |
| Dec 2025 | $45.9M | 250.76% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $91.0M |
| PTCT PTC Therapeutics, Inc. compare | $10.5M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.2M |
| ORKA Oruka Therapeutics, Inc. compare | −$100.9M |
| KOD Kodiak Sciences Inc. compare | −$158.5M |
| CGON CG Oncology, Inc. compare | −$178.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$271.3M |
| IMVT Immunovant, Inc. compare | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$496.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on LGND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement